Zurcher Kantonalbank Zurich Cantonalbank Acquires 2,872 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 6.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,783 shares of the company’s stock after buying an additional 2,872 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Option Care Health were worth $1,610,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of OPCH. Vanguard Group Inc. increased its holdings in Option Care Health by 11.8% in the 3rd quarter. Vanguard Group Inc. now owns 19,319,352 shares of the company’s stock valued at $624,981,000 after acquiring an additional 2,037,162 shares during the last quarter. Third Point LLC lifted its position in shares of Option Care Health by 55.7% in the third quarter. Third Point LLC now owns 5,450,659 shares of the company’s stock worth $176,329,000 after buying an additional 1,950,659 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Option Care Health during the 3rd quarter valued at approximately $36,239,000. Fiera Capital Corp bought a new stake in Option Care Health in the 3rd quarter worth approximately $21,370,000. Finally, Riverbridge Partners LLC increased its stake in Option Care Health by 49.5% in the 4th quarter. Riverbridge Partners LLC now owns 1,792,012 shares of the company’s stock worth $60,373,000 after acquiring an additional 593,706 shares during the last quarter. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Stock Performance

NASDAQ OPCH opened at $29.93 on Thursday. The company has a market cap of $5.20 billion, a P/E ratio of 20.36, a P/E/G ratio of 1.73 and a beta of 1.22. The business’s 50 day moving average price is $32.13 and its 200-day moving average price is $31.52. Option Care Health, Inc. has a fifty-two week low of $24.23 and a fifty-two week high of $35.74. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.33 and a current ratio of 1.77.

Option Care Health (NASDAQ:OPCH) last posted its quarterly earnings data on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. Option Care Health had a net margin of 6.21% and a return on equity of 18.78%. The business had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter in the previous year, the business posted $0.21 earnings per share. The business’s revenue was up 12.8% compared to the same quarter last year. Sell-side analysts predict that Option Care Health, Inc. will post 1.13 earnings per share for the current year.

Analysts Set New Price Targets

OPCH has been the subject of a number of recent research reports. Jefferies Financial Group raised their target price on shares of Option Care Health from $36.00 to $38.00 and gave the company a “buy” rating in a report on Monday, March 4th. Barrington Research reissued an “outperform” rating and issued a $38.00 price objective on shares of Option Care Health in a research note on Wednesday.

Insiders Place Their Bets

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. bought 35,000 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were purchased at an average price of $31.55 per share, with a total value of $1,104,250.00. Following the completion of the purchase, the director now owns 269,528 shares in the company, valued at approximately $8,503,608.40. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.64% of the stock is owned by insiders.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.